---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-048377"
form_type: "8-K"
ticker: "ABT"
cik: "0000001800"
company_name: "ABBOTT LABORATORIES"
filed_at: "2026-07-16T11:36:19+00:00"
generated_at: "2026-07-16T11:40:07.483589+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Abbott Q2 adjusted EPS $1.31; raises FY2026 EPS guidance to $5.45-$5.60

## Summary
- Q2 reported sales $12.6B (+13.0% reported, +4.8% comparable); GAAP EPS $0.53, adjusted EPS $1.31.
- Full-year 2026 adjusted EPS guidance raised to $5.45-$5.60 from $5.38-$5.58; comparable sales growth reaffirmed at 6.5%-7.5%.
- Medical Devices comparable sales +8.4%; Diabetes Care CGM comparable sales +9.5%.
- Returned $2.1B to shareholders in Q2 via dividends and share repurchases.

## SEC filing metadata
- accession: 0001628280-26-048377
- form_type: 8-K
- ticker: ABT
- cik: 0000001800
- company_name: ABBOTT LABORATORIES
- filed_at: 2026-07-16T11:36:19+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800/000162828026048377/0001628280-26-048377-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800/000162828026048377/abt-20260716.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-048377
- JSON: https://secwatch.observer/filing/0001628280-26-048377.json
- Plain text: https://secwatch.observer/filing/0001628280-26-048377.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.